Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 985,589
  • Shares Outstanding, K 165,924
  • Annual Sales, $ 203,070 K
  • Annual Income, $ -54,840 K
  • EBIT $ 21 M
  • EBITDA $ 36 M
  • 60-Month Beta 0.61
  • Price/Sales 3.42
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 122.66% (+42.30%)
  • Historical Volatility 41.32%
  • IV Percentile 92%
  • IV Rank 52.71%
  • IV High 190.36% on 02/05/26
  • IV Low 47.20% on 09/17/25
  • Expected Move (DTE 15) 1.02 (16.80%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 377
  • Volume Avg (30-Day) 1,428
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 36,837
  • Open Int (30-Day) 26,943
  • Expected Range 5.05 to 7.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.00
  • Number of Estimates 4
  • High Estimate 0.02
  • Low Estimate -0.03
  • Prior Year -0.06
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.73 +5.93%
on 03/03/26
7.26 -16.39%
on 02/11/26
-1.01 (-14.27%)
since 02/04/26
3-Month
5.73 +5.93%
on 03/03/26
8.42 -27.91%
on 01/08/26
-0.65 (-9.67%)
since 12/04/25
52-Week
3.65 +66.30%
on 03/05/25
10.08 -39.78%
on 11/05/25
+2.32 (+61.87%)
since 03/04/25

Most Recent Stories

More News
Xeris Biopharma: Q4 Earnings Snapshot

Xeris Biopharma: Q4 Earnings Snapshot

XERS : 6.07 (+2.19%)
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million ...

XERS : 6.07 (+2.19%)
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

Four Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028

XERS : 6.07 (+2.19%)
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

Conference Call to be Held at 8:30 a.m. ET

XERS : 6.07 (+2.19%)
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

Anticipates full year 2025 total revenue of $292 million, exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the prior year ...

XERS : 6.07 (+2.19%)
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 6.07 (+2.19%)
The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away

Corcept shares crash as the FDA rejects its application for relacorilant. But is it worth buying CORT stock on the pullback?

CORT : 35.69 (+1.16%)
XERS : 6.07 (+2.19%)
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 6.07 (+2.19%)
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Total product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to $285-$290 million; previously $280-$290...

XERS : 6.07 (+2.19%)
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

Conference Call to be Held at 8:30 a.m. ET

XERS : 6.07 (+2.19%)

Business Summary

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and...

See More

Key Turning Points

3rd Resistance Point 6.46
2nd Resistance Point 6.30
1st Resistance Point 6.18
Last Price 6.07
1st Support Level 5.91
2nd Support Level 5.75
3rd Support Level 5.63

See More

52-Week High 10.08
Fibonacci 61.8% 7.62
Fibonacci 50% 6.86
Fibonacci 38.2% 6.11
Last Price 6.07
52-Week Low 3.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar